Literature DB >> 17618132

Frequency of seizures and epilepsy in neurological HIV-infected patients.

C Kellinghaus1, C Engbring, S Kovac, G Möddel, F Boesebeck, M Fischera, K Anneken, K Klönne, D Reichelt, S Evers, I W Husstedt.   

Abstract

BACKGROUND: Infection with the human immunodeficiency virus (HIV) is associated both with infections of the central nervous system and with neurological deficits due to direct effects of the neurotropic virus. Seizures and epilepsy are not rare among HIV-infected patients. We investigated the frequency of acute seizures and epilepsy of patients in different stages of HIV infection. In addition, we compared the characteristics of patients who experienced provoked seizures only with those of patients who developed epilepsy.
METHODS: The database of the Department of Neurology, University of Münster, was searched for patients with HIV infection admitted between 1992 and 2004. Their charts were reviewed regarding all available sociodemographic, clinical, neurophysiological, imaging and laboratory data, therapy and outcome. Stage of infection according to the CDC classification and the epileptogenic zone were determined.
RESULTS: Of 831 HIV-infected patients treated in our department, 51 (6.1%) had seizures or epilepsy. Three of the 51 patients (6%) were diagnosed with epilepsy before the onset of the HIV infection. Fourteen patients (27%) only had single or few provoked seizures in the setting of acute cerebral disorders (eight patients), drug withdrawal or sleep withdrawal (two patients), or of unknown cause (four patients). Thirty-four patients (67%) developed epilepsy in the course of their HIV infection. Toxoplasmosis (seven patients), progressive multifocal leukencephalopathy (seven patients) and other acute or subacute cerebral infections (five patients) were the most frequent causes of seizures. EEG data of 38 patients were available. EEG showed generalized and diffuse slowing only in 9 patients, regional slowing in 14 patients and regional slowing and epileptiform discharges in 1 patient. Only 14 of the patients had normal EEG. At the last contact, the majority of the patients (46 patients=90%) were on highly active antiretroviral therapy (HAART). Twenty-seven patients (53%) were on anticonvulsant therapy (gabapentin: 14 patients, carbamazepine: 9 patients, valproate: 2 patients, phenytoin: 1 patient, lamotrigine: 1 patient). Patients with only provoked seizures had no epilepsy risk factors except HIV infection, and were less likely to be infected via intravenous drug abuse.
CONCLUSIONS: Seizures are a relevant neurological symptom during the course of HIV infection. Although in some patients seizures only occur provoked by acute disease processes, the majority of patients with new onset seizures eventually develops epilepsy and require anticonvulsant therapy. Intravenous drug abuse and the presence of non-HIV-associated risk factors for epilepsy seem to be associated with the development of chronic seizures in this patient group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618132     DOI: 10.1016/j.seizure.2007.05.017

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  29 in total

1.  Epilepsy: Issues with antiepileptic drug use in HIV-infected patients.

Authors:  Bruce J Brew; Julia Thompson
Journal:  Nat Rev Neurol       Date:  2012-03-13       Impact factor: 42.937

2.  Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs.

Authors:  Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

3.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

4.  Cognitive impairment and psychiatric morbidity in HIV+ Zambians with new-onset seizure.

Authors:  Lisa Kalungwana; Melissa A Elafros; Omar K Siddiqi; Christopher M Bositis; Izukanji Sikazwe; Igor J Koralnik; William H Theodore; Gretchen L Birbeck
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

Review 5.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

6.  New-onset seizure in HIV-infected adult Zambians: A search for causes and consequences.

Authors:  Omar K Siddiqi; Melissa A Elafros; Christopher M Bositis; Igor J Koralnik; William H Theodore; Jason F Okulicz; Lisa Kalungwana; Michael J Potchen; Izukanji Sikazwe; Gretchen L Birbeck
Journal:  Neurology       Date:  2016-12-21       Impact factor: 9.910

7.  Acute EEG findings in HIV-infected Zambian adults with new-onset seizure.

Authors:  Omar K Siddiqi; Melissa A Elafros; Izukanji Sikazwe; Gretchen L Birbeck; Lisa Kalungwana; Michael J Potchen; Christopher M Bositis; Igor J Koralnik; William H Theodore
Journal:  Neurology       Date:  2015-03-04       Impact factor: 9.910

8.  Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

Authors:  P Vivithanaporn; G Heo; J Gamble; H B Krentz; A Hoke; M J Gill; C Power
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

9.  The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study.

Authors:  Jason F Okulicz; Greg A Grandits; Jacqueline A French; Emilio Perucca; Jomy M George; Michael L Landrum; Edward P Acosta; Gretchen L Birbeck
Journal:  Epilepsy Res       Date:  2012-07-24       Impact factor: 3.045

Review 10.  [Highly active antiretroviral therapy of neuro-AIDS. Side effects on the nervous system and interactions].

Authors:  I W Husstedt; D Reichelt; E Neuen-Jakob; K Hahn; F Kästner; R von Einsiedel; B Vielhaber; G Arendt; S Evers
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.